Abstract
Urinary creatinine excretion rate (CER) is an established marker of muscle mass. Low CER has been linked to poor coronary artery disease outcomes, but a link between CER and acute stroke prognosis has not been previously explored. We prospectively collected data from patients with acute stroke (ischemic or hemorrhagic) within 24 hours from symptom onset in a Neurological and Neurosurgery Intensive Care Unit in Taiwan. Baseline CER (mg/d) was calculated by urine creatinine concentration in morning spot urine multiplies 24-hour urine volume on the second day of admission. Patients were divided into 3 tertiles with highest, middle, and lowest CER. Primary endpoint was poor outcome defined as modified Rankin Scale 3-6 at 6 months. Among 156 critically ill acute stroke patients meeting study entry criteria, average age was 67.9 years, and 83 (53.2%) patients had ischemic stroke. Patients with lowest CER (vs. highest CER) had a high risk of poor outcome at 6-month after adjustment (odds ratio 4.96, 95% confidence interval 1.22 to 20.15, p value = 0.025). In conclusion, low baseline CER, a marker of muscle mass, was independently associated with poor 6-month outcome among critically ill acute stroke patients. We speculate that preservation of muscle mass through exercise or protein-energy supplement might be helpful for improving prognosis in severe stroke patients.
Keywords: Urine creatinine excretion rate, stroke, critically ill, outcome.
Current Neurovascular Research
Title:Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients
Volume: 12 Issue: 1
Author(s): Chia-Yu Hsu, Yi-Ling Wu, Chun-Yu Cheng, Jiann-Der Lee, Ying-Chih Huang, Ming-Hsueh Lee, Chih-Ying Wu, Huan-Lin Hsu, Ya-Hui Lin, Yen-Chu Huang, Hsin-Ta Yang, Jen-Tsung Yang, Meng Lee and Bruce Ovbiagele
Affiliation:
Keywords: Urine creatinine excretion rate, stroke, critically ill, outcome.
Abstract: Urinary creatinine excretion rate (CER) is an established marker of muscle mass. Low CER has been linked to poor coronary artery disease outcomes, but a link between CER and acute stroke prognosis has not been previously explored. We prospectively collected data from patients with acute stroke (ischemic or hemorrhagic) within 24 hours from symptom onset in a Neurological and Neurosurgery Intensive Care Unit in Taiwan. Baseline CER (mg/d) was calculated by urine creatinine concentration in morning spot urine multiplies 24-hour urine volume on the second day of admission. Patients were divided into 3 tertiles with highest, middle, and lowest CER. Primary endpoint was poor outcome defined as modified Rankin Scale 3-6 at 6 months. Among 156 critically ill acute stroke patients meeting study entry criteria, average age was 67.9 years, and 83 (53.2%) patients had ischemic stroke. Patients with lowest CER (vs. highest CER) had a high risk of poor outcome at 6-month after adjustment (odds ratio 4.96, 95% confidence interval 1.22 to 20.15, p value = 0.025). In conclusion, low baseline CER, a marker of muscle mass, was independently associated with poor 6-month outcome among critically ill acute stroke patients. We speculate that preservation of muscle mass through exercise or protein-energy supplement might be helpful for improving prognosis in severe stroke patients.
Export Options
About this article
Cite this article as:
Hsu Chia-Yu, Wu Yi-Ling, Cheng Chun-Yu, Lee Jiann-Der, Huang Ying-Chih, Lee Ming-Hsueh, Wu Chih-Ying, Hsu Huan-Lin, Lin Ya-Hui, Huang Yen-Chu, Yang Hsin-Ta, Yang Jen-Tsung, Lee Meng and Ovbiagele Bruce, Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients, Current Neurovascular Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567202612666150102151455
DOI https://dx.doi.org/10.2174/1567202612666150102151455 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Impact of Glycemic Variability and Hypoglycemia on the Mortality and Length of Hospital Stay among Elderly Patients in Brazil
Current Diabetes Reviews The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
Current Clinical Pharmacology Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Association of SORL1 Gene Variants with Hippocampal and Cerebral Atrophy and Alzheimer's Disease
Current Alzheimer Research Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats
Drug Metabolism Letters MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Xanthan and Locust Bean Gum (from Ceratonia siliqua) Matrix Tablets for Oral Controlled Delivery of Metoprolol Tartrate
Current Drug Therapy Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design